Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes (NCT01143532) | Clinical Trial Compass
CompletedNot Applicable
Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes
United States26 participantsStarted 2010-08-12
Plain-language summary
Background:
\- Genetic variation in a particular chromosome is a major contributor to the increased risk for kidney disease that is common in people of African descent, although the specific gene, mutations, and other aspects of the variations remain to be determined. By studying the outcomes of kidney transplant in donors and recipients of African descent, researchers hope to better understand the effects of this genetic variation on the success of kidney transplants.
Objectives:
\- To examine possible connections between genetic variations and kidney transplant outcomes for donors and recipients.
Eligibility:
* Participants in kidney transplant where both donor and recipient were of black African descent.
* Eligible transplants include both living donor and deceased donor.
Design:
* The study will involve one visit of up to 8 hours.
* All participants will provide a detailed personal and family medical history.
* All participants will provide blood and urine samples, including a 24-hour urine collection, to test kidney function and collect material for genetic testing.
* Donor participants will also have a magnetic resonance imaging (MRI) scan of their remaining kidney.
Who can participate
Age range
18 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. African descent donor and African descent recipient
. Kidney transplant performed Jan 1995 - Dec 2006.
. First kidney transplant
. Kidney only transplant (excluding transplant of any other organ at any other time).
Exclusion criteria
. We will exclude donors whose kidneys were used in transplants in which two organs were transplanted, e.g. pancreas and kidney, either simultaneously or at separate times. We will exclude donors whose kidneys were used in second or subsequent transplants. Rationale: dual organ transplants and serial transplants are more complicated clinical situations and renal allograft survival may be shorter and thus not comparable with other kidney transplants.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Whether variation in other donor genes might contribute to donor and recipient outcomes
Timeframe: 1995-2006
Trial details
NCT IDNCT01143532
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)